Protara Therapeutics
TARA
Protara Therapeutics (TARA) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$0.31
- EPS estimate
- −$0.38
- EPS surprise
- +19.27%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Nov 10, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 10, 2025 | −$0.38 | −$0.31 | +19.27% | $0.00 | SEC |
| Q2 2025 | Aug 11, 2025 | −$0.39 | −$0.35 | +9.09% | $0.00 | SEC |
| Q1 2025 | May 8, 2025 | −$0.45 | −$0.29 | +35.81% | $0.00 | SEC |
| Q4 2024 | Mar 5, 2025 | −$0.57 | −$0.48 | +15.04% | $0.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.52 | −$0.50 | +3.85% | $0.00 | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.80 | −$0.45 | +43.75% | $0.00 | SEC |
| Q1 2024 | May 2, 2024 | −$0.92 | −$0.97 | −5.43% | $0.00 | SEC |
| Q4 2023 | Mar 13, 2024 | −$0.92 | −$0.90 | +1.91% | $0.00 | SEC |
| Q3 2023 | Nov 3, 2023 | −$0.98 | −$0.87 | +11.22% | $0.00 | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.88 | −$1.00 | −14.29% | $0.00 | SEC |
| Q1 2023 | May 4, 2023 | −$0.88 | −$0.80 | +8.75% | $0.00 | SEC |
| Q4 2022 | Mar 8, 2023 | −$0.75 | −$3.46 | −361.33% | $0.00 | SEC |
| Q3 2022 | Nov 3, 2022 | −$0.76 | −$0.68 | +10.14% | $0.00 | — |
| Q2 2022 | Aug 9, 2022 | −$0.94 | −$0.80 | +14.59% | $0.00 | — |
| Q1 2022 | May 5, 2022 | −$0.90 | −$0.96 | −6.28% | $0.00 | — |
| Q4 2021 | Mar 9, 2022 | −$0.94 | −$0.91 | +3.53% | $0.00 | — |
| Q3 2021 | Nov 4, 2021 | −$1.01 | −$0.96 | +4.95% | $0.00 | — |
| Q2 2021 | Aug 5, 2021 | −$1.05 | −$1.14 | −8.31% | $0.00 | — |
| Q1 2021 | May 6, 2021 | −$0.73 | −$1.20 | −65.13% | $0.00 | — |
| Q4 2020 | Mar 11, 2021 | −$0.54 | −$0.79 | −45.41% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Protara Therapeutics (TARA) last report earnings?
Protara Therapeutics last reported on Nov 10, 2025, covering fiscal Q3 2025.
Did TARA beat earnings estimates?
Yes. Protara Therapeutics reported EPS of −$0.31 for Q3 2025 against a −$0.38 estimate — a 19.27% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.